Certifications
GMP
评分
(0)
(0)
(0)
(0)
(0)
评论
筛选：
排序方式：
暂无评论。
暂无评论。
Nanjing Hanxin Pharmaceutical Technology Co., Ltd., restructured in 2021 from the China R&D Center of US-based Amphastar Pharmaceuticals, Inc. with registered capital of RMB 183 million, stands as a fast-growing biopharmaceutical leader specializing in peptides, proteins and polysaccharides.
留下您的评分和评论